Skip to main content
Equibles
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc · Webcasts, Transcripts & Audio

Track KNSA — free

Use KNSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KNSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$76.26 +0.47 (+0.62%)
Russell 2000 member Rebalance outlook locked
Market Cap
$11.72B
Shares
156.05M
Volume · Oct 5 231.27K Avg daily vol (3M) 602.43K

Kiniksa Pharmaceuticals International, plc Webcasts

Earnings calls, investor updates, investor days and conferences for Kiniksa Pharmaceuticals International, plc (KNSA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲719.6% $99.14M $224.09M '22 Q3 22-11-01 · $61.88M $4.46M '22 Q4 23-02-28 ▲50.2% $48.34M −$12.27M '23 Q1 23-05-02 ▲165% $71.47M $14.97M '23 Q2 23-07-25 ▼32.4% $67.05M −$13.86M '23 Q3 23-10-31 ▲34.8% $83.39M $25.24M '23 Q4 24-02-28 ▲65.2% $79.86M −$17.70M '24 Q1 24-04-23 ▲52% $108.63M −$3.91M '24 Q2 24-07-23 ▲67.4% $112.21M −$12.69M '24 Q3 24-10-29 ▲46.9% $122.54M −$8.89M '24 Q4 25-02-25 ▲72.5% $137.78M $8.54M '25 Q1 25-04-29 ▲44.3% $156.80M $17.83M '25 Q2 25-07-29 ▲61.2% $180.85M $18.43M '25 Q3 25-10-28 ▲65% $202.13M $14.20M '25 Q4 26-02-24 LATEST ▲55.5% $214.27M $22.59M '26 Q1 26-04-28
Conference
Investor event
2026-09-09
Kiniksa Pharmaceuticals International, plc (KNSA) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-12
Kiniksa Pharmaceuticals International, plc (KNSA) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Confident tone KPL-387 Phase 3 advancement ARCALIST commercial momentum ACC clinical guidelines dissemination
Results not yet reported
Audio Transcript Slides 8-K10-Q
Investor Update
Investor event
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) July 2026 Investor Update
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-09
Kiniksa Pharmaceuticals International, plc (KNSA) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Kiniksa Pharmaceuticals International, plc (KNSA) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call
Revenue
$214.27M
▲ 55.5% YoY
Diluted EPS
$0.27
▲ 145.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Confident tone ARCALYST commercial growth KPL-387 pipeline development KPL-1161 early pipeline
Revenue
$202.13M*
▲ 65% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Confident tone Patient Adherence and Duration of Therapy ARCALYST Commercial Growth Recurrent Pericarditis Market Penetration
Revenue
$180.85M
▲ 61.2% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript
Confident tone ARCALYST commercial execution KPL-387 pipeline (recurrent pericarditis) Recurrent pericarditis market leadership
Revenue
$156.80M
▲ 44.3% YoY
Diluted EPS
$0.23
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Confident tone ARCALYST commercial performance and guidance raise KPL-387 pipeline development in recurrent pericarditis Medicare Part D / IRA affordability changes
Revenue
$137.78M
▲ 72.5% YoY
Diluted EPS
$0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Confident tone KPL-387 program announcement ARCALYST commercial growth Pipeline portfolio prioritization
Revenue
$122.54M*
▲ 46.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript
Confident tone ARCALYST commercial execution First recurrence (earlier-line) prescribing Abiprubart pipeline in Sjogren's disease
Revenue
$112.21M
▲ 67.4% YoY
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Phase 2b Guidance and outlook
Revenue
$108.63M
▲ 52% YoY
Diluted EPS
$-0.06
▼ 128.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2024 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart pipeline / Sjögren's Disease RESONANCE Registry and steroid-sparing paradigm
Revenue
$79.86M
▲ 65.2% YoY
Diluted EPS
$-0.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2023 Earnings Call Transcript
Confident tone ARCALYST commercial performance Abiprubart Phase II clinical data Abiprubart Phase IIb in new indication
Revenue
$83.39M*
▲ 34.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2023 Earnings Call Transcript
Revenue
$67.05M
▼ 32.4% YoY
Diluted EPS
$-0.20
▼ 106.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2023 Earnings Call Transcript
Revenue
$71.47M
▲ 165% YoY
Diluted EPS
$0.21
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2023 Earnings Call Transcript
Revenue
$48.34M
▲ 50.2% YoY
Diluted EPS
$-0.18
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2022 Earnings Call Transcript
Revenue
$61.88M*
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2022 Earnings Call Transcript
Revenue
$99.14M
▲ 719.6% YoY
Diluted EPS
$3.18
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2022 Earnings Call Transcript
Revenue
$26.97M
▲ 250.1% YoY
Diluted EPS
$-0.29
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2022 Earnings Call Transcript
Revenue
$32.19M
Diluted EPS
$-0.36
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2021 Earnings Call Transcript
Revenue
$12.10M
Diluted EPS
$-0.44
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2021 Earnings Call Transcript
Revenue
$7.70M
Diluted EPS
$-0.61
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1730430 CUSIP G52694109 13F (30d) 5 filings 5 filers Visit website Investor relations